The impact of pain management on quality of life

被引:222
作者
Katz, N [1 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Pain Trials Ctr, Boston, MA 02115 USA
关键词
analgesia; coxibs; COX-2; pain; quality of life; symptom distress;
D O I
10.1016/S0885-3924(02)00411-6
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Although its inclusion in medical research is relatively recent and its interpretation is often variable, quality of life;S increasing being recognized as one of the most important Parameters to be measured in the evaluation of medical therapies, including those for pain management. Pain, when it is not effectively treated and relieved, has a detrimental effect on all aspects of quality of life. This negative impart has been found to span every age and every type and source of pain in which it has been studied. Effective analgesic therapy has been shown to improve quality of life by relieving pain. Opioid analgesics, cyclooxygenase (COX)-2 inhibitors (or coxibs), and several adjuvant analgesics for neuropathic pain Now been demonstrated to significantly improve quality-of-life scores in Patients with Pain. Coxib Provide effective, well-tolerated analgesia without some of the issues faced with opioids-benefits that should translate into improved quality of life. Recent studies have demonstrated that the COX-2 inhibitor rofecoxib significantly improves quality of life in Patients with osteoarthritis and chronic, lower back pain. Quality-of-life measurements, especially symptom distress scales, can also be used as sensitive means of differentiating one agent from another in the same class. In future pharmacotherapeutic research, quality of life should be included as an outcome domain as are the traditionally measured variables of efficacy and safety. In particular future studies of coxibs should include symptom distress scores as important quality-of-life measurements, to identify meaningful differences between this new class of analgesics and nonselective nonsteroidal anti-inflammatory drugs. (C) US. Cancer Pain Relief Committee, 2000.
引用
收藏
页码:S38 / S47
页数:10
相关论文
共 31 条
  • [1] Abbott FV, 1998, J PSYCHIATR NEUROSCI, V23, P13
  • [2] ALLAN L, 2001, EUROPEAN LEAGUE RHEU
  • [3] Physical symptoms distress index - A sensitive tool to evaluate the impact of pharmacological agents on quality of life
    Anderson, RB
    Hollenberg, NK
    Williams, GH
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (07) : 693 - 700
  • [4] Anderson RB., 1994, DRUG INF J, V28, P89, DOI 10.1177/009286159402800112
  • [5] [Anonymous], 1996, Quality of Life and Pharmacoeconomics in Clinical Trials
  • [6] Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center
    Becker, N
    Thomsen, AB
    Olsen, AK
    Sjogren, P
    Bech, P
    Eriksen, J
    [J]. PAIN, 1997, 73 (03) : 393 - 400
  • [7] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
    Bombardier, C
    Laine, L
    Reicin, A
    Shapiro, D
    Burgos-Vargas, R
    Davis, B
    Day, R
    Ferraz, MB
    Hawkey, CJ
    Hochberg, MC
    Kvien, TK
    Schnitzer, TJ
    Weaver, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) : 1520 - 1528
  • [8] Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129
  • [9] PAIN AND ITS TREATMENT IN OUTPATIENTS WITH METASTATIC CANCER
    CLEELAND, CS
    GONIN, R
    HATFIELD, AK
    EDMONSON, JH
    BLUM, RH
    STEWART, JA
    PANDYA, KJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) : 592 - 596
  • [10] Ehrich EW, 2001, AM J MANAG CARE, V7, P609